PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19690166-9	2009	Furthermore, the ERRgamma inverse agonist GSK5182 enhances the interaction of SMILE with ERRgamma and SMILE-mediated repression.	GSK5182	42-49	estrogen related receptor gamma	Homo sapiens	17-25
19690166-9	2009	Furthermore, the ERRgamma inverse agonist GSK5182 enhances the interaction of SMILE with ERRgamma and SMILE-mediated repression.	GSK5182	42-49	CREB/ATF bZIP transcription factor	Homo sapiens	78-83
19690166-9	2009	Furthermore, the ERRgamma inverse agonist GSK5182 enhances the interaction of SMILE with ERRgamma and SMILE-mediated repression.	GSK5182	42-49	estrogen related receptor gamma	Homo sapiens	89-97
19690166-9	2009	Furthermore, the ERRgamma inverse agonist GSK5182 enhances the interaction of SMILE with ERRgamma and SMILE-mediated repression.	GSK5182	42-49	CREB/ATF bZIP transcription factor	Homo sapiens	102-107
19690166-10	2009	Knockdown of SMILE or SIRT1 blocks the repressive effect of GSK5182.	GSK5182	60-67	CREB/ATF bZIP transcription factor	Homo sapiens	13-18
19690166-10	2009	Knockdown of SMILE or SIRT1 blocks the repressive effect of GSK5182.	GSK5182	60-67	sirtuin 1	Homo sapiens	22-27
19690166-11	2009	Moreover, chromatin immunoprecipitation assays revealed that GSK5182 augments the association of SMILE and SIRT1 on the promoter of the ERRgamma target PDK4.	GSK5182	61-68	CREB/ATF bZIP transcription factor	Homo sapiens	97-102
19690166-11	2009	Moreover, chromatin immunoprecipitation assays revealed that GSK5182 augments the association of SMILE and SIRT1 on the promoter of the ERRgamma target PDK4.	GSK5182	61-68	sirtuin 1	Homo sapiens	107-112
19690166-11	2009	Moreover, chromatin immunoprecipitation assays revealed that GSK5182 augments the association of SMILE and SIRT1 on the promoter of the ERRgamma target PDK4.	GSK5182	61-68	estrogen related receptor gamma	Homo sapiens	136-144
19690166-11	2009	Moreover, chromatin immunoprecipitation assays revealed that GSK5182 augments the association of SMILE and SIRT1 on the promoter of the ERRgamma target PDK4.	GSK5182	61-68	pyruvate dehydrogenase kinase 4	Homo sapiens	152-156
19690166-12	2009	GSK5182 and adenoviral overexpression of SMILE cooperate to repress ERRgamma-induced PDK4 gene expression, and this repression is released by overexpression of a catalytically defective SIRT1 mutant.	GSK5182	0-7	estrogen related receptor gamma	Homo sapiens	68-76
19690166-12	2009	GSK5182 and adenoviral overexpression of SMILE cooperate to repress ERRgamma-induced PDK4 gene expression, and this repression is released by overexpression of a catalytically defective SIRT1 mutant.	GSK5182	0-7	pyruvate dehydrogenase kinase 4	Homo sapiens	85-89
19690166-12	2009	GSK5182 and adenoviral overexpression of SMILE cooperate to repress ERRgamma-induced PDK4 gene expression, and this repression is released by overexpression of a catalytically defective SIRT1 mutant.	GSK5182	0-7	sirtuin 1	Homo sapiens	186-191
34191077-5	2021	Studies with hepatocyte specific ERRgamma knockout mice or treatment with an ERRgamma-specific inverse agonist, GSK5182 (40 mg/kg), indicated that CCl4-induced hepatic TGF-beta2 production is ERRgamma dependent.	GSK5182	112-119	chemokine (C-C motif) ligand 4	Mus musculus	147-151
34191077-5	2021	Studies with hepatocyte specific ERRgamma knockout mice or treatment with an ERRgamma-specific inverse agonist, GSK5182 (40 mg/kg), indicated that CCl4-induced hepatic TGF-beta2 production is ERRgamma dependent.	GSK5182	112-119	transforming growth factor, beta 2	Mus musculus	168-177
34191077-9	2021	Finally, GSK5182 diminished CCl4-induced fibrogenic response through inhibition of ERRgamma-mediated TGF-beta2 production.	GSK5182	9-16	chemokine (C-C motif) ligand 4	Mus musculus	28-32
34191077-9	2021	Finally, GSK5182 diminished CCl4-induced fibrogenic response through inhibition of ERRgamma-mediated TGF-beta2 production.	GSK5182	9-16	transforming growth factor, beta 2	Mus musculus	101-110
33612148-0	2021	The estrogen-related receptor gamma modulator, GSK5182, inhibits osteoclast differentiation and accelerates osteoclast apoptosis.	GSK5182	47-54	estrogen related receptor gamma	Homo sapiens	4-35
34810288-8	2021	The different TXF concentrations studied significantly improved the percentage of viability of cardiomyocytes with hypoxic injury, and the LDH release, apoptotic rate, caspase-3 activity, and levels of cleaved caspase-3 protein were reduced in the injured cells.	GSK5182	14-17	caspase 3	Homo sapiens	168-177
34810288-8	2021	The different TXF concentrations studied significantly improved the percentage of viability of cardiomyocytes with hypoxic injury, and the LDH release, apoptotic rate, caspase-3 activity, and levels of cleaved caspase-3 protein were reduced in the injured cells.	GSK5182	14-17	caspase 3	Homo sapiens	210-219
33612148-4	2021	In the present study, we explored the effects of an ERRgamma-specific modulator, GSK5182, on ERRgamma-regulated osteoclast differentiation and survival.	GSK5182	81-88	estrogen related receptor gamma	Homo sapiens	52-60
33612148-4	2021	In the present study, we explored the effects of an ERRgamma-specific modulator, GSK5182, on ERRgamma-regulated osteoclast differentiation and survival.	GSK5182	81-88	estrogen related receptor gamma	Homo sapiens	93-101
33612148-5	2021	Interestingly, GSK5182 increased ERRgamma protein levels much as does GSK4716, which is an ERRgamma agonist.	GSK5182	15-22	estrogen related receptor gamma	Homo sapiens	33-41
33612148-5	2021	Interestingly, GSK5182 increased ERRgamma protein levels much as does GSK4716, which is an ERRgamma agonist.	GSK5182	15-22	estrogen related receptor gamma	Homo sapiens	91-99
33612148-7	2021	GSK5182 also attenuated RANKL-mediated expression of c-Fos and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), pivotal transcription factors for osteoclastogenesis.	GSK5182	0-7	TNF superfamily member 11	Homo sapiens	24-29
33612148-7	2021	GSK5182 also attenuated RANKL-mediated expression of c-Fos and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), pivotal transcription factors for osteoclastogenesis.	GSK5182	0-7	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	53-58
33612148-7	2021	GSK5182 also attenuated RANKL-mediated expression of c-Fos and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), pivotal transcription factors for osteoclastogenesis.	GSK5182	0-7	nuclear factor of activated T cells 1	Homo sapiens	63-112
33612148-7	2021	GSK5182 also attenuated RANKL-mediated expression of c-Fos and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), pivotal transcription factors for osteoclastogenesis.	GSK5182	0-7	nuclear factor of activated T cells 1	Homo sapiens	114-120
33612148-9	2021	GSK5182 strongly blocked the phosphorylation of IkappaBalpha, c-Jun N-terminal kinase, and extracellular signal-regulated kinase in response to RANKL.	GSK5182	0-7	NFKB inhibitor alpha	Homo sapiens	48-60
33612148-9	2021	GSK5182 strongly blocked the phosphorylation of IkappaBalpha, c-Jun N-terminal kinase, and extracellular signal-regulated kinase in response to RANKL.	GSK5182	0-7	TNF superfamily member 11	Homo sapiens	144-149
33612148-10	2021	GSK5182 also suppressed NF-kappaB promoter activity in a dose-dependent manner.	GSK5182	0-7	nuclear factor kappa B subunit 1	Homo sapiens	24-33
33612148-12	2021	Together, these results suggest that GSK5182, a synthetic ERRgamma modulator, may have potential in treating disorders related to bone resorption.	GSK5182	37-44	estrogen related receptor gamma	Homo sapiens	58-66
32998264-9	2020	Finally, an inverse agonist of ERRgamma, GSK5182, markedly inhibits IL-6 induced hepatic BMP6 expression in vitro and in vivo.	GSK5182	41-48	estrogen-related receptor gamma	Mus musculus	31-39
33434621-6	2021	HPB2-induced upregulation of BDNF was attenuated by GSK5182, an antagonist of ERRgamma, and siRNA-mediated ERRgamma silencing.	GSK5182	52-59	brain derived neurotrophic factor	Homo sapiens	29-33
32998264-9	2020	Finally, an inverse agonist of ERRgamma, GSK5182, markedly inhibits IL-6 induced hepatic BMP6 expression in vitro and in vivo.	GSK5182	41-48	interleukin 6	Mus musculus	68-72
32998264-9	2020	Finally, an inverse agonist of ERRgamma, GSK5182, markedly inhibits IL-6 induced hepatic BMP6 expression in vitro and in vivo.	GSK5182	41-48	bone morphogenetic protein 6	Mus musculus	89-93
32173553-5	2020	The ERRgamma agonist GSK4716 increased DAT and TH expression, and the ERRgamma inverse agonist GSK5182 attenuated the retinoic acid-induced upregulation of DAT and TH in differentiated SH-SY5Y cells.	GSK5182	95-102	estrogen related receptor gamma	Homo sapiens	70-78
32173553-5	2020	The ERRgamma agonist GSK4716 increased DAT and TH expression, and the ERRgamma inverse agonist GSK5182 attenuated the retinoic acid-induced upregulation of DAT and TH in differentiated SH-SY5Y cells.	GSK5182	95-102	solute carrier family 6 member 3	Homo sapiens	156-159
32173553-5	2020	The ERRgamma agonist GSK4716 increased DAT and TH expression, and the ERRgamma inverse agonist GSK5182 attenuated the retinoic acid-induced upregulation of DAT and TH in differentiated SH-SY5Y cells.	GSK5182	95-102	tyrosine hydroxylase	Homo sapiens	164-166
28382164-6	2017	Treatment with dexamethasone (an anti-inflammation drug) or GSK5182 (an ERRgamma inverse agonist) hindered macrophage recruitment to the inflamed sites.	GSK5182	60-67	estrogen related receptor gamma	Homo sapiens	72-80
32079653-7	2020	We demonstrate that pharmacological inhibition of ERRgamma with the selective inverse agonist GSK5182 increases antitumor efficacy of the chemotherapeutic paclitaxel on poor outcome BCa tumor organoids.	GSK5182	94-101	estrogen related receptor gamma	Homo sapiens	50-58
29959872-3	2018	The purpose of this study was to investigate the effect of the three common polymorphic variants of hFMO3 (V257M, E158K and E308G) on the metabolism and clearance of three structurally similar compounds: tamoxifen (breast cancer medication), clomiphene (infertility medication) and GSK5182 (antidiabetic lead molecule).	GSK5182	282-289	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	100-105
30019168-5	2018	In a therapeutic approach, we now tested ERRgamma inverse agonist GSK5182 as regulator of fibrinogen levels in mouse hyperfibrinogenemia caused by diet-induced obesity and in mouse hepatocytes.	GSK5182	66-73	fibrinogen beta chain	Homo sapiens	90-100
28750085-7	2017	Moreover, overexpression of ERRgamma was sufficient to increase fibrinogen gene expression, whereas treatment with GSK5182, a selective inverse agonist of ERRgamma led to its attenuation in cell culture.	GSK5182	115-122	estrogen related receptor gamma	Homo sapiens	155-163
32197603-3	2020	Here, Escherichia coli (E. coli) JM109 cells over-expressing the recombinant human FMO3 (flavin-containing monooxygenase isoform 3) were used for the conversions of clomiphene, dasatinib, GSK5182 and tozasertib to their corresponding N-oxide metabolites.	GSK5182	188-195	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	83-87
32197603-3	2020	Here, Escherichia coli (E. coli) JM109 cells over-expressing the recombinant human FMO3 (flavin-containing monooxygenase isoform 3) were used for the conversions of clomiphene, dasatinib, GSK5182 and tozasertib to their corresponding N-oxide metabolites.	GSK5182	188-195	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	89-130
32197603-6	2020	In addition, FMO3 shows high regio-selectivity in metabolizing GSK5182 where only the (Z) isomer is monooxygenated.	GSK5182	63-70	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	13-17
32197603-7	2020	CONCLUSIONS: The study shows the successful use of human FMO3-based whole-cell as a biocatalyst for the efficient synthesis of drug metabolites including regio-selective reactions involving GSK5182, a new candidate against type 2 diabetes mellitus.	GSK5182	190-197	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	57-61
31479733-7	2019	Finally, an ERRgamma inverse agonist, GSK5182, significantly ameliorates fatty liver disease in chronically alcohol-fed mice through inhibition of SREBP-1c-mediated fat accumulation.	GSK5182	38-45	estrogen related receptor gamma	Homo sapiens	12-20
31479733-7	2019	Finally, an ERRgamma inverse agonist, GSK5182, significantly ameliorates fatty liver disease in chronically alcohol-fed mice through inhibition of SREBP-1c-mediated fat accumulation.	GSK5182	38-45	sterol regulatory element binding transcription factor 1	Mus musculus	147-155
30019168-10	2018	Finally, GSK5182 (40 mg/kg) strongly inhibits the ACEA (10 mg/kg) or HFD-mediated induction of fibrinogen level in mice.	GSK5182	9-16	fibrinogen beta chain	Homo sapiens	95-105
30019168-11	2018	Taken together, targeting ERRgamma with its inverse agonist GSK5182 represents a promising therapeutic strategy for ameliorating hyperfibrinogenemia.	GSK5182	60-67	estrogen related receptor gamma	Homo sapiens	26-34
27455076-8	2016	Finally, GSK5182, an ERRgamma inverse agonist, significantly inhibited hepatic CB1 receptor-mediated FGF21 gene expression and secretion.	GSK5182	9-16	cannabinoid receptor 1 (brain)	Mus musculus	79-82
27236015-3	2016	The results were comparable to those for GSK5182 (4), a leading ERRgamma inverse agonist ligand.	GSK5182	41-48	estrogen related receptor gamma	Homo sapiens	64-72
27455076-8	2016	Finally, GSK5182, an ERRgamma inverse agonist, significantly inhibited hepatic CB1 receptor-mediated FGF21 gene expression and secretion.	GSK5182	9-16	fibroblast growth factor 21	Mus musculus	101-106
26771593-1	2016	GSK5182 (4) is currently one of the lead compounds for the development of estrogen-related receptor gamma (ERRgamma) inverse agonists.	GSK5182	0-7	estrogen related receptor gamma	Homo sapiens	74-105
26940882-9	2016	Treatment of PLC/PRF/5 cells with siRNA-ERRgamma or GSK5182 inhibited proliferation through G1 arrest, increased expression of p21 and p27 and decreased expression of phosphorylated retinoblastoma protein.	GSK5182	52-59	heparan sulfate proteoglycan 2	Homo sapiens	13-16
26940882-9	2016	Treatment of PLC/PRF/5 cells with siRNA-ERRgamma or GSK5182 inhibited proliferation through G1 arrest, increased expression of p21 and p27 and decreased expression of phosphorylated retinoblastoma protein.	GSK5182	52-59	H3 histone pseudogene 16	Homo sapiens	127-130
26940882-9	2016	Treatment of PLC/PRF/5 cells with siRNA-ERRgamma or GSK5182 inhibited proliferation through G1 arrest, increased expression of p21 and p27 and decreased expression of phosphorylated retinoblastoma protein.	GSK5182	52-59	interferon alpha inducible protein 27	Homo sapiens	135-138
26940882-10	2016	GSK5182-induced reactive oxygen species also suppressed the proliferation of PLC/PRF/5 cells.	GSK5182	0-7	heparan sulfate proteoglycan 2	Homo sapiens	77-80
26940882-12	2016	Moreover, the results provide a rationale for the use of ERRgamma inhibitors such as GSK5182 as potential therapeutic agents.	GSK5182	85-92	estrogen related receptor gamma	Homo sapiens	57-65
26771593-1	2016	GSK5182 (4) is currently one of the lead compounds for the development of estrogen-related receptor gamma (ERRgamma) inverse agonists.	GSK5182	0-7	estrogen related receptor gamma	Homo sapiens	107-115
23050013-8	2012	Finally, GSK5182, an inverse agonist of ERRgamma, strongly inhibited the hypoxia-mediated induction of PDK4 protein and promoter activity.	GSK5182	9-16	estrogen related receptor gamma	Homo sapiens	40-48
26338896-4	2015	Here, we evaluated the role of ERRgamma in the regulation of NIS function in ATC cells using GSK5182, an inverse agonist of ERRgamma.	GSK5182	93-100	estrogen related receptor gamma	Homo sapiens	124-132
26338896-8	2015	To examine whether the GSK5182-induced NIS functional activity can be affected by inhibition of the MAP kinase pathway, the MAP kinase activity and levels of radioiodine uptake were determined after application of a mitogen-activated protein kinase kinase (MEK) inhibitor to GSK5182-treated cells.	GSK5182	23-30	mitogen-activated protein kinase kinase 7	Homo sapiens	257-260
26338896-10	2015	RESULTS: Treatment with GSK5182 resulted in dose- and time-dependent increases in iodide uptake in ATC cells, which were accompanied by both the downregulation of ERRgamma protein and the activation of extracellular signal-regulated kinase (ERK) 1/2.	GSK5182	24-31	estrogen related receptor gamma	Homo sapiens	163-171
26338896-10	2015	RESULTS: Treatment with GSK5182 resulted in dose- and time-dependent increases in iodide uptake in ATC cells, which were accompanied by both the downregulation of ERRgamma protein and the activation of extracellular signal-regulated kinase (ERK) 1/2.	GSK5182	24-31	mitogen-activated protein kinase 3	Homo sapiens	202-249
26348907-8	2015	Overexpression of ERRgamma led to increased bile acid levels, whereas an inverse agonist of ERRgamma, GSK5182, reduced CYP7A1 expression and bile acid synthesis.	GSK5182	102-109	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	119-125
26348907-9	2015	Finally, GSK5182 significantly reduced hepatic CB1 receptor-mediated induction of CYP7A1 expression and bile acid synthesis in alcohol-treated mice.	GSK5182	9-16	cannabinoid receptor 1 (brain)	Mus musculus	47-50
26348907-9	2015	Finally, GSK5182 significantly reduced hepatic CB1 receptor-mediated induction of CYP7A1 expression and bile acid synthesis in alcohol-treated mice.	GSK5182	9-16	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	82-88
25796334-5	2015	This study evaluated the role of ERRgamma in the ischemic retina and the anti-VEGF potential of GSK5182, a selective inverse agonist of ERRgamma.	GSK5182	96-103	vascular endothelial growth factor A	Mus musculus	78-82
25796334-5	2015	This study evaluated the role of ERRgamma in the ischemic retina and the anti-VEGF potential of GSK5182, a selective inverse agonist of ERRgamma.	GSK5182	96-103	estrogen-related receptor gamma	Mus musculus	136-144
25796334-8	2015	Transient transfection of RGC-5 cells revealed that ERRgamma regulated Vegfa expression and this was inhibited by GSK5182.	GSK5182	114-121	estrogen-related receptor gamma	Mus musculus	52-60
25796334-8	2015	Transient transfection of RGC-5 cells revealed that ERRgamma regulated Vegfa expression and this was inhibited by GSK5182.	GSK5182	114-121	vascular endothelial growth factor A	Mus musculus	71-76
25796334-9	2015	Intravitreal injection of GSK5182 into the OIR model at P14 inhibited retinal Vegfa mRNA expression at P17.	GSK5182	26-33	S100 calcium binding protein A9 (calgranulin B)	Mus musculus	56-59
25796334-9	2015	Intravitreal injection of GSK5182 into the OIR model at P14 inhibited retinal Vegfa mRNA expression at P17.	GSK5182	26-33	vascular endothelial growth factor A	Mus musculus	78-83
25796334-9	2015	Intravitreal injection of GSK5182 into the OIR model at P14 inhibited retinal Vegfa mRNA expression at P17.	GSK5182	26-33	family with sequence similarity 72, member A	Mus musculus	103-106
25796334-10	2015	GSK5182 suppresses hypoxia-induced VEGF expression via ERRgamma; therefore, ERRgamma could be a treatment target for ischemic retinopathies.	GSK5182	0-7	vascular endothelial growth factor A	Mus musculus	35-39
25796334-10	2015	GSK5182 suppresses hypoxia-induced VEGF expression via ERRgamma; therefore, ERRgamma could be a treatment target for ischemic retinopathies.	GSK5182	0-7	estrogen-related receptor gamma	Mus musculus	55-63
25796334-10	2015	GSK5182 suppresses hypoxia-induced VEGF expression via ERRgamma; therefore, ERRgamma could be a treatment target for ischemic retinopathies.	GSK5182	0-7	estrogen-related receptor gamma	Mus musculus	76-84
25451157-0	2015	In vitro metabolism of an estrogen-related receptor gamma modulator, GSK5182, by human liver microsomes and recombinant cytochrome P450s.	GSK5182	69-76	estrogen related receptor gamma	Homo sapiens	26-57
25451157-1	2015	GSK5182 (4-[(Z)-1-[4-(2-dimethylaminoethyloxy)phenyl]-hydroxy-2-phenylpent-1-enyl]phenol) is a specific inverse agonist for estrogen-related receptor gamma, a member of the orphan nuclear receptor family that has important functions in development and homeostasis.	GSK5182	0-7	estrogen related receptor gamma	Homo sapiens	124-155
25451157-1	2015	GSK5182 (4-[(Z)-1-[4-(2-dimethylaminoethyloxy)phenyl]-hydroxy-2-phenylpent-1-enyl]phenol) is a specific inverse agonist for estrogen-related receptor gamma, a member of the orphan nuclear receptor family that has important functions in development and homeostasis.	GSK5182	9-88	estrogen related receptor gamma	Homo sapiens	124-155
25451157-7	2015	GSK5182 N-demethylation and hydroxylation is mainly mediated by CYP3A4, whereas FMO1 and FMO3 contribute to the formation of GSK5182 N-oxide from GSK5182.	GSK5182	0-7	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-70
25543835-12	2015	Taken together, these results indicate that TXF promotes the proliferation via accelerating the G(1)/S transition, and induces chondrogenic differentiation in BMSCs by activation of the Ihh signaling pathway in association with TGF-beta1.	GSK5182	44-47	Indian hedgehog signaling molecule	Rattus norvegicus	186-189
25543835-12	2015	Taken together, these results indicate that TXF promotes the proliferation via accelerating the G(1)/S transition, and induces chondrogenic differentiation in BMSCs by activation of the Ihh signaling pathway in association with TGF-beta1.	GSK5182	44-47	transforming growth factor, beta 1	Rattus norvegicus	228-237
24466039-5	2014	Overexpression of ERRgamma by adenovirus significantly increased expression of CREBH as well as C-reactive protein (CRP), whereas either knockdown of ERRgamma or inhibition of ERRgamma by ERRgamma specific inverse agonist, GSK5182, substantially inhibited ER stress-mediated induction of CREBH and CRP.	GSK5182	223-230	estrogen related receptor gamma	Homo sapiens	18-26
24466039-8	2014	Moreover, chronic alcoholic hepatosteatosis, as well as the diabetic obese condition significantly increased CRP gene expression, and this increase was significantly attenuated by GSK5182 treatment.	GSK5182	180-187	C-reactive protein	Homo sapiens	109-112
22549789-7	2012	We also demonstrate that GSK5182, an inverse agonist of ERRgamma, specifically inhibits the transcriptional activity of ERRgamma in a PGC-1alpha dependent manner.	GSK5182	25-32	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	134-144
23050013-8	2012	Finally, GSK5182, an inverse agonist of ERRgamma, strongly inhibited the hypoxia-mediated induction of PDK4 protein and promoter activity.	GSK5182	9-16	pyruvate dehydrogenase kinase 4	Homo sapiens	103-107
21911493-9	2011	Finally, an inverse agonist of ERRgamma, GSK5182, restores the impaired insulin signaling induced by LIPIN1-mediated PKCepsilon activation.	GSK5182	41-48	estrogen related receptor gamma	Homo sapiens	31-39
21911493-9	2011	Finally, an inverse agonist of ERRgamma, GSK5182, restores the impaired insulin signaling induced by LIPIN1-mediated PKCepsilon activation.	GSK5182	41-48	lipin 1	Homo sapiens	101-107
21911493-9	2011	Finally, an inverse agonist of ERRgamma, GSK5182, restores the impaired insulin signaling induced by LIPIN1-mediated PKCepsilon activation.	GSK5182	41-48	protein kinase C epsilon	Homo sapiens	117-127